UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Recruiting now · Phase 1
Conditions studied: Relapsed/Refractory B-cell Malignancies
In brief
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.
Key facts
- Study ID
- NCT06590961
- Run by
- Ubix Therapeutics, Inc.
- People needed
- 94
- Starts
- 2025-02-20
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2025-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Gabrail Cancer Center — Canton, Oklahoma, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Asan Medical Center — Seoul, Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, Seoul, South Korea (enrolling)
- The Catholic University of Korea, Seoul St. Mary's Hospital — Seoul, Seoul, South Korea (enrolling)
- The Catholic University of Korea, Yeouido St. Mary's Hospital — Seoul, Seoul, South Korea (enrolling)
- MICS Centrum Medyczne Toruń — Torun, Kuyavian-Pomeranian Voivodeship, Poland
- Pratia, MTZ Clinical Research — Warsaw, Mazowieckie Voivodeship, Poland
- Pratia, Oncology Katowice — Katowice, Silesian Voivodeship, Poland
- AidPort — Grodzisk Wielkopolski, Wielkopolskie Voivodeship, Poland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.